【bangor savings car loan rates】AstraZeneca's COVID-19 Vaccine Trial Delays May Worsen As FDA Widens Investigation
AstraZeneca Plc’s
(NYSE:
AZN
) coronavirus vaccine development program could hit by further delays,bangor savings car loan rates as the Food and Drug Administration has widened the scope of its probe into the halted trial, Reuters
reported
Wednesday.
What Happened:
The federal agency is inquiring whether side effects similar to the one seen in the COVID-19 vaccine trial — transverse myelitis — also emerged in trials of other vaccines designed by Oxford University, AstraZeneca's partner, Reuters said, citing people familiar with the matter.
The vaccines reportedly under review use a modified adenovirus as a vector and target illnesses such as the Middle East Respiratory Syndrome and the flu.
Oxford’s vaccines use a chimpanzee adenovirus, ChAdOx1, unlike other vaccine developers that use a human variant.
A review of research papers by Reuters found that in one trial, a serious side effect event cited by researchers was classified as unrelated to the vaccine.
Another complication that may affect the trial: the Reuters report said the FDA is requesting data from the British pharmaceutical firm that is in a different format than the one used by the FDA.
People familiar with the developments told Reuters the FDA’s actions aren't an indicator there are safety issues related to any of the vaccines under review.
Benzinga is covering every angle of how the coronavirus affects the financial world.
For daily updates,
sign up for our coronavirus newsletter
.
Why It Matters:
Last month, AstraZeneca’s coronavirus vaccine trials were halted after a volunteer developed symptoms of a serious
neurological disorder
known as transverse myelitis.
The Cambridge, United Kingdom-based company has resumed trials in India, South Africa, Brazil and the U.K.
Some scientists have questioned why the drugmaker’s COVID-19 vaccine trials remain suspended in the U.S.
While AstraZeneca experiences delays,
Pfizer Inc
(NYSE:
PFE
) is seeking FDA clearance to expand its late-stage trials by adding more participants.
AZN Price Action:
AstraZeneca shares ended Wednesday's session down 0.54% at $54.81 and fell slightly further after-hours.
See more from Benzinga
Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas
Regeneron Says COVID-19 Antibody Cocktail Helped Non-Hospitalized Patients Heal Faster In Early Trials
Sanofi CEO Says COVID-19 Vaccine Development Process Accelerated, Not Side-Stepped
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
View comments
相关文章
Global Vision Care Market (2020 to 2025) - Featuring Alcon, Carl Zeiss and Hoya Among Others
Dublin, Dec. 02, 2020 (GLOBE NEWSWIRE) -- The"Vision Care: Global Markets"report has been added toRe2024-09-29Morning News Call - U.S., January 2
To access the newsletter, click on the link:http://share.thomsonreuters.com/assets/newsletters/morni2024-09-29Why Thermo Fisher Scientific Inc. (NYSE:TMO) Could Be Worth Watching
Let’s talk about the popular Thermo Fisher Scientific Inc. (NYSE:TMO). The company’s shares saw sign2024-09-29BRIEF-Guangdong Tecsun Science & Technology Scraps Asset Restructuring
Feb 1 (Reuters) - Guangdong Tecsun Science & Technology Co Ltd:* SAYS IT SCRAPS ASSET RESTRUCTURING2024-09-29- London, June 05, 2020 (GLOBE NEWSWIRE) -- Livestock diagnostics include consumables comprising of th2024-09-29
BRIEF-Inno-Tech Says Wang Yu Resigned As Chief Executive Officer
Feb 1 (Reuters) - Inno-Tech Holdings Ltd:* ZHENG PIN HAS BEEN APPOINTED AS EXECUTIVE DIRECTOR AND VI2024-09-29
最新评论